McKesson Europe AG

HMSE:CLS1 Stock Report

Market Cap: €5.0b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

McKesson Europe Valuation

Is CLS1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CLS1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CLS1 (€24.4) is trading above our estimate of fair value (€17.47)

Significantly Below Fair Value: CLS1 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CLS1?

Key metric: As CLS1 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CLS1. This is calculated by dividing CLS1's market cap by their current revenue.
What is CLS1's PS Ratio?
PS Ratio0.5x
Sales€9.26b
Market Cap€4.96b

Price to Sales Ratio vs Peers

How does CLS1's PS Ratio compare to its peers?

The above table shows the PS ratio for CLS1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.5x
ILM1 Medios
0.2x6.1%€334.7m
HAEK HAEMATO
0.3x4.4%€91.0m
SYAB SYNLAB
0.9x4.4%€2.4b
FME Fresenius Medical Care
0.6x3.8%€12.4b
CLS1 McKesson Europe
0.5xn/a€5.0b

Price-To-Sales vs Peers: CLS1 is expensive based on its Price-To-Sales Ratio (0.5x) compared to the peer average (0.5x).

Price to Sales Ratio vs Industry

How does CLS1's PS Ratio compare vs other companies in the DE Healthcare Industry?

1 CompanyPrice / SalesEstimated GrowthMarket Cap
TLIK Arzneiwerk VIDA
0.08xn/aUS$4.67m
No more companies available in this PS range
CLS1 0.5xIndustry Avg. 0.6xNo. of Companies4PS00.40.81.21.62+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CLS1 is good value based on its Price-To-Sales Ratio (0.5x) compared to the European Healthcare industry average (0.7x)

Price to Sales Ratio vs Fair Ratio

What is CLS1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CLS1 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate CLS1's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.1b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

7D

-1.0%

1Y

-38.8%

LNA Santé

€244.4m

Engages in the management and operation of health establishments.

2N3

€23.25

7D

-6.1%

1Y

16.0%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%